Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir,a Novel Pangenotypic NS3/4A Protease Inhibitor

Abstract

Background

Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1–6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with other HCV PIs. In a 3-day Phase Ib monotherapy study in patients infected with HCV GT1a, 1b, 2, 3 and 4, VOX was well-tolerated and resulted in maximal mean viral load reduction >3 log₁₀ IU/ml at the 100 mg dose across all genotypes evaluated. This report characterizes the HCV NS3 RAS in the study.

Methods

The NS3 gene was amplified and successfully deep sequenced using MiSeq for 66 patients at baseline and 61 patients post-baseline using 15% and 1% assay cutoffs.

Results

With a 15% assay cutoff, pretreatment HCV NS3 RAS were present in the HCV of 38% (9/24) of patients with GT1a and 5% (1/19) with GT3a; there were no pre-treatment NS3 RAS present in patients with GT1b (n=6), GT2 (n=7) or GT4 (n=4). In patients with and without pretreatment NS3 RAS, ≥3.4 log₁₀ mean maximal viral load reductions over 3 days of VOX administration were observed. The majority of patients did not have detectable treatment-emergent NS3 RAS and only 12% (7/53) and 26% (14/53) had emergent NS3 RAS using 15% and 1% cutoffs, respectively. No NS3 RAS were detected in patients with GT2 or GT4. A156T or A156V were the most prevalent emergent NS3 RAS in patients with GT1a or GT1b infection, but were not observed in patients with GT3 infection.

Conclusions

The lack of selection of NS3 RAS in the majority of patients demonstrates a high resistance barrier for VOX. ClinicalTrails.gov identifier NCT02185794.

References

Cooke

G.S.

, Lemoine

, Thursz

Viral hepatitis and the global burden of disease: a need to regroup.

J Viral Hepat 2013; 20: 600–601.

Mohd Hanafiah

, Groeger

, Flaxman

A.D.

, Wiersma

S.T.

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.

Hepatology 2013; 57: 1333–1342.

The Polaris Observatory HCV Collaborators.

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Lancet 2017; 2: 161–176.

Lauer

G.M.

, Walker

B.D.

Hepatitis C virus infection.

N Engl J Med 2001; 345: 41–52.

European Association for Study of Liver.

EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

J Hepatol 2014; 60: 392–420.

AASLD IDSA HCV Guidance Panel.

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Hepatology 2015; 62: 932–954.

Lam

B.P.

, Jeffers

, Younoszai

, Fazel

, Younossi

Z.M.

The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment.

Therap Adv Gastroenterol 2015; 8: 298–312.

Holmes

J.A.

, Thompson

A.J.

Interferon-free combination therapies for the treatment of hepatitis C: current insights.

Hepat Med 2015; 7: 51–70.

Solbach

, Wedemeyer

The new era of interferon-free treatment of chronic hepatitis C.

Viszeralmedizin 2015; 31: 290–296.

10.

Timm

, Roggendorf

Sequence diversity of hepatitis C virus: implications for immune control and therapy.

World J Gastroenterol 2007; 13: 4808–4817.

11.

Ford

, Kirby

, Singh

Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.

Bull World Health Organ 2012; 90: 540–550.

12.

Simmonds

, Alberti

, Alter

H.J.

A proposed system for the nomenclature of hepatitis C viral genotypes.

Hepatology 1994; 19: 1321–1324.

13.

Bullock

G.C.

, Bruns

D.E.

, Haverstick

D.M.

Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes.

Clin Chem 2002; 48: 2147–2154.

14.

Romano

K.P.

, Ali

, Aydin

The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.

PLoS Pathog 2012; 8: e1002832.

15.

Romano

K.P.

, Laine

J.M.

, Deveau

L.M.

, Cao

, Massi

, Schiffer

C.A.

Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease.

J Virol 2011; 85: 6106–6116.

16.

Romano

K.P.

, Ali

, Royer

W.E.

, Schiffer

C.A.

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.

Proc Natl Acad Sci U S A 2010; 107: 20986–20991.

17.

Summa

, Ludmerer

S.W.

, McCauley

J.A.

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.

Antimicrob Agents Chemother 2012; 56: 4161–4167.

18.

Taylor

J.G.

, Appleby

, Barauskas

Preclinical profile of the pangenotypic HCV NS3/4A protease inhibitor GS-9857.

J Hepatol 2015; 62: S681.

19.

Robinson

, Yang

, Sun

S.C.

Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a.

Antimicrob Agents Chemother 2010; 54: 3099–3106.

20.

, Corsa

A.C.

, Xu

In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.

Antiviral Res 2013; 100: 439–445.

21.

Peng

, Yu

, Xu

Development of robust hepatitis C virus genotype 4 subgenomic replicons.

Gastroenterology 2013; 144: 59–61.e6.

22.

Vrolijk

J.M.

, Kaul

, Hansen

B.E.

A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.

J Virol Methods 2003; 110: 201–209.

23.

Y.P.

, Ramirez

, Gottwein

J.M.

Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.

Proc Natl Acad Sci U S A 2012; 109: E1101–E1110.

24.

, Peng

, Chan

Robust and persistent replication of genotype 6a hepatitis C virus replicon in cell culture.

Antimicrob Agents Chemother 2014; 58: 2638–2646.

25.

Rodriguez-Torres

, Glass

, Hill

GS-9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double-blind, dose-ranging Phase 1 study.

J Viral Hepat 2016; 23: 614–622.

26.

Hedskog

, Dvory-Sobol

, Gontcharova

Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.

J Viral Hepat 2015; 22: 871–881.

27.

Robinson

, Yang

, Sun

S.C.

Novel HCV reporter replicon cell lines enable efficient antiviral screening against genotype 1a.

Antimicrob Agents Chemother 2010; 54: 3099–3106.

28.

Lohmann

, Korner

, Koch

, Herian

, Theilmann

, Bartenschlager

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

Science 1999; 285: 110–113.

29.

Cheng

, Chan

, Yang

Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system.

Antimicrob Agents Chemother 2011; 55: 2197–2205.

30.

Shih

I.H.

, Vliegen

, Peng

Mechanistic characterization of GS-9190 (tegobuvir), a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.

Antimicrob Agents Chemother 2011; 55: 4196–4203.

31.

Lawitz

E.J.

, O'Riordan

W.D.

, Asatryan

Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection.

Antimicrob Agents Chemother 2015; 60: 1546–1555.

32.

Pilot-Matias

, Tripathi

, Cohen

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.

Antimicrob Agents Chemother 2015; 59: 988–997.

33.

Lenz

, Verbinnen

, Fevery

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

J Hepatol 2015; 62: 1008–1014.

34.

Kieffer

T.L.

, Sarrazin

, Miller

J.S.

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.

Hepatology 2007; 46: 631–639.

35.

Susser

, Welsch

, Wang

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.

Hepatology 2009; 50: 1709–1718.

36.

Wyles

, Dvory-Sobol

, Svarovskaia

E.S.

Post-treatment resistance analysis of hepatitis C virus from Phase II and III clinical trials of ledipasvir/sofosbuvir.

J Hepatol 2017; 66: 703–710.

37.

Dvory-Sobol

, Wong

K.A.

, Ku

K.S.

Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients.

Antimicrob Agents Chemother 2012; 56: 5289–5295.

38.

Lawitz

, Sulkowski

, Jacobson

Safety, tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease, in patients with chronic HCV genotype 1 infection.

Hepatology 2008; 48: 403A.

39.

Manns

M.P.

, Gane

, Rodriguez-Torres

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized Phase II study.

Hepatology 2012; 56: 884–893.

40.

Xue

, Pan

, Yang

, Liu

, Yao

Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.

Antiviral Res 2012; 93: 126–137.

41.

Pan

, Xue

, Zhang

, Liu

, Yao

Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: a computational study.

Biochim Biophys Acta 2012; 1820: 1526–1534.

42.

Bourlière

, Gordon

S.C.

, Flamm

S.L.

Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection.

N Engl J Med 2017; 376: 2134–2146.

43.

Jacobson

I.M.

, Lawitz

, Gane

E.J.

Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 Phase 3 randomized trials.

Gastroenterology 2017; 153: 113–122.

44.

Sullivan

J.C.

, De Meyer

, Bartels

D.J.

Evolution of treatment-emergent resistant variants in telaprevir Phase 3 clinical trials.

Clin Infect Dis 2013; 57: 221–229.

45.

Howe

A.Y.

, Long

, Nickle

Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C.

Antiviral Res 2015; 113: 71–78.

46.

Buti

, Gordon

S.C.

, Zuckerman

Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE.

Clin Infect Dis 2016; 62: 32–36.

47.

Wang

, Sun

J.H.

, O'Boyle

D.R.

Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.

Antimicrob Agents Chemother 2013; 57: 2054–2065.

48.

Lawitz

, Poordad

, Wells

Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV.

Hepatology 2017; 65: 1803–1809.

49.

Lawitz

, Reau

, Hinestrosa

Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, Phase 2 trial.

Gastroenterology 2016; 151: 893–901.e1.

50.

Gane

E.J.

, Kowdley

K.V.

, Pound

Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, Phase 2 trial.

Gastroenterology 2016; 151: 902–909.